These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27489211)

  • 1. Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV-1106, a Long-Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects.
    Cohen-Barak O; Barkay H; Rasamoelisolo M; Butler K; Yamada K; Bassan M; Yoon E; Spiegelstein O
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):331-342. PubMed ID: 27489211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Pharmacodynamics, and Safety of a Long-Acting Human Growth Hormone (MOD-4023) in Healthy Japanese and Caucasian Adults.
    Kramer WG; Jaron-Mendelson M; Koren R; Hershkovitz O; Hart G
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):554-563. PubMed ID: 29136343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys.
    Ashkenazi N; Rosenstock M; Hallak H; Bassan M; Rasamoelisolo M; Leuschner J; Shinar D
    Growth Horm IGF Res; 2016; 30-31():16-21. PubMed ID: 27552669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
    Rasmussen MH; Olsen MW; Alifrangis L; Klim S; Suntum M
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
    Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency.
    Cohen-Barak O; Sakov A; Rasamoelisolo M; Bassan M; Brown K; Mendzelevski B; Spiegelstein O
    Eur J Endocrinol; 2015 Nov; 173(5):541-51. PubMed ID: 26286586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
    Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
    J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
    Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study.
    Owada Y; Okazaki M; Ikeda T; Yamamoto R; Minami K; Takahashi K; Hirato T; Mita Y; Yamamoto T; Tanizawa K; Sonoda H; Sato Y
    Growth Horm IGF Res; 2022 Dec; 67():101500. PubMed ID: 36113378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.
    Osborn BL; Sekut L; Corcoran M; Poortman C; Sturm B; Chen G; Mather D; Lin HL; Parry TJ
    Eur J Pharmacol; 2002 Dec; 456(1-3):149-58. PubMed ID: 12450581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile.
    Rasmussen MH; Jensen L; Anderson TW; Klitgaard T; Madsen J
    Clin Endocrinol (Oxf); 2010 Dec; 73(6):769-76. PubMed ID: 20718773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.
    Cohen-Barak O; Wildeman J; van de Wetering J; Hettinga J; Schuilenga-Hut P; Gross A; Clark S; Bassan M; Gilgun-Sherki Y; Mendzelevski B; Spiegelstein O
    J Clin Pharmacol; 2015 May; 55(5):573-83. PubMed ID: 25524052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
    Rasmussen MH; Bysted BV; Anderson TW; Klitgaard T; Madsen J
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
    Rasmussen MH; Janukonyté J; Klose M; Marina D; Tanvig M; Nielsen LF; Höybye C; Andersen M; Feldt-Rasmussen U; Christiansen JS
    J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free and total insulin-like growth factors and insulin-like growth factor binding proteins during 14 days of growth hormone administration in healthy adults.
    Skjaerbaek C; Frystyk J; Møller J; Christiansen JS; Orskov H
    Eur J Endocrinol; 1996 Dec; 135(6):672-7. PubMed ID: 9025711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults.
    Oscarsson J; Johannsson G; Johansson JO; Lundberg PA; Lindstedt G; Bengtsson BA
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):63-8. PubMed ID: 9059559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
    Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
    J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
    Søndergaard E; Klose M; Hansen M; Hansen BS; Andersen M; Feldt-Rasmussen U; Laursen T; Rasmussen MH; Christiansen JS
    J Clin Endocrinol Metab; 2011 Mar; 96(3):681-8. PubMed ID: 21177789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life.
    Aguiar-Oliveira MH; Gill MS; de A Barretto ES; Alcântara MR; Miraki-Moud F; Menezes CA; Souza AH; Martinelli CE; Pereira FA; Salvatori R; Levine MA; Shalet SM; Camacho-Hubner C; Clayton PE
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4118-26. PubMed ID: 10566659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.